Research programme: topical wound treatment - AlphaRxAlternative Names: ARX606T
Latest Information Update: 23 Sep 2011
At a glance
- Originator AlphaRx
- Developer AlphaRx; Riso Pharma Tech
- Class Growth factors
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Wounds